Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.53 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1402043 | 0.97 | ADORA2A (0.60) | ADORA2AADORA3CDK1CCNE2CCNE1 | |
| SCHEMBL4559022 | 0.92 | ADORA2A (0.57) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| Trifluoroacetic Acid SCHEMBL4110783 | 0.91 | ADORA2A (0.63) | ADORA2AADORA3CDK1CCNE2CCNE1 | |
| Trifluoroacetic Acid SCHEMBL1402000 | 0.88 | ADORA2A (0.66) | ADORA2AADORA3CDK1CCNE2CCNE1 | |
| SCHEMBL241222 | 0.88 | ADORA2A (0.53) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| SCHEMBL4481823 | 0.88 | ADORA2A (0.55) | ADORA2AADORA3 | |
| SCHEMBL242887 | 0.87 | ADORA2A (0.53) | ADORA2AADORA3 | |
| SCHEMBL4111499 | 0.87 | ADORA2A (0.48) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| SCHEMBL243159 | 0.87 | ADORA2A (0.52) | ADORA2AADORA3 | |
| SCHEMBL243669 | 0.86 | ADORA2A (0.53) | ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | CYP3A43, OXER1, OPRM1 | ADORA2A 2082/4885ADORA3 554/4885CDK1 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.